Figure 5
From: Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
NbA42 and NbA213 recognize ABCC3-expressing orthotopic brain tumors. (a) Workflow of the experimental setup of targeting analysis of nanobodies. Nanobodies were administered at 15 mg·kg−1 i.p. in mice bearing intracranial glioblastoma tumors generated from the indicated cell lines. Tumor targeting was examined using prospective ex vivo flow cytometry, 1 h after systemic injection. Image created with BioRender.com (accessed on November 5th, 2022). (b) Assessment of the potential detection of ABCC3-expressing orthotopically implanted glioblastoma tumors by NbA42 and NbA213. (c) Analysis of BBB integrity by quantification of i.p. administered Evans blue in the brain of mice with intact, mock surgery brains (PBS), orthotopic U251 and U-87 MG tumors and their contralateral hemisphere. Graphic depict the amount of Evans blue stain per gram of tissue (mean ± SD; n = 3).
